Universal Health Services, Inc.

NYSE:UHS Stock Report

Market Cap: US$11.9b

Universal Health Services Valuation

Is UHS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UHS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UHS ($178.37) is trading below our estimate of fair value ($500.69)

Significantly Below Fair Value: UHS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UHS?

Key metric: As UHS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for UHS. This is calculated by dividing UHS's market cap by their current earnings.
What is UHS's PE Ratio?
PE Ratio11.5x
EarningsUS$1.03b
Market CapUS$11.90b

Price to Earnings Ratio vs Peers

How does UHS's PE Ratio compare to its peers?

The above table shows the PE ratio for UHS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average17.4x
THC Tenet Healthcare
3.8x-39.2%US$12.2b
EHC Encompass Health
21.6x9.6%US$9.4b
ENSG Ensign Group
31.5x18.1%US$7.6b
ACHC Acadia Healthcare Company
12.8x10.6%US$3.5b
UHS Universal Health Services
11.5x8.3%US$11.9b

Price-To-Earnings vs Peers: UHS is good value based on its Price-To-Earnings Ratio (11.5x) compared to the peer average (17.4x).

Price to Earnings Ratio vs Industry

How does UHS's PE Ratio compare vs other companies in the US Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
THC Tenet Healthcare
3.8x-39.2%US$12.17b
NEUE NeueHealth
2.2xn/aUS$60.83m
IDXG Interpace Biosciences
2.7xn/aUS$11.66m
No more companies available in this PE range
UHS 11.5xIndustry Avg. 21.9xNo. of Companies10PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: UHS is good value based on its Price-To-Earnings Ratio (11.5x) compared to the US Healthcare industry average (21.9x).

Price to Earnings Ratio vs Fair Ratio

What is UHS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UHS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.5x
Fair PE Ratio27.5x

Price-To-Earnings vs Fair Ratio: UHS is good value based on its Price-To-Earnings Ratio (11.5x) compared to the estimated Fair Price-To-Earnings Ratio (27.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UHS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$178.37
US$238.21
+33.5%
9.7%US$274.00US$197.00n/a15
Dec ’25US$205.00
US$240.81
+17.5%
8.3%US$274.00US$211.00n/a15
Nov ’25US$205.26
US$247.81
+20.7%
9.0%US$275.00US$211.00n/a15
Oct ’25US$224.66
US$240.20
+6.9%
7.1%US$274.00US$219.00n/a16
Sep ’25US$237.97
US$235.76
-0.9%
7.9%US$267.00US$189.00n/a16
Aug ’25US$215.82
US$230.27
+6.7%
8.7%US$256.00US$186.00n/a15
Jul ’25US$182.20
US$198.53
+9.0%
9.2%US$236.00US$156.00n/a15
Jun ’25US$189.80
US$194.20
+2.3%
7.6%US$226.00US$156.00n/a15
May ’25US$170.19
US$189.79
+11.5%
6.5%US$208.00US$156.00n/a14
Apr ’25US$175.21
US$188.00
+7.3%
6.9%US$208.00US$156.00n/a14
Mar ’25US$171.12
US$178.23
+4.2%
9.8%US$208.00US$144.00n/a13
Feb ’25US$163.14
US$162.38
-0.5%
8.5%US$190.00US$140.00n/a13
Jan ’25US$152.44
US$154.62
+1.4%
8.1%US$175.00US$140.00n/a13
Dec ’24US$137.70
US$150.15
+9.0%
6.5%US$170.00US$139.00US$205.0013
Nov ’24US$125.39
US$151.77
+21.0%
6.4%US$170.00US$140.00US$205.2613
Oct ’24US$125.73
US$155.86
+24.0%
6.4%US$172.00US$142.00US$224.6614
Sep ’24US$134.57
US$158.13
+17.5%
7.1%US$183.00US$142.00US$237.9715
Aug ’24US$139.26
US$157.33
+13.0%
7.7%US$183.00US$140.00US$215.8215
Jul ’24US$157.77
US$153.87
-2.5%
7.0%US$178.00US$139.00US$182.2015
Jun ’24US$131.14
US$152.87
+16.6%
5.9%US$170.00US$139.00US$189.8015
May ’24US$148.19
US$148.20
+0.007%
7.6%US$165.00US$124.00US$170.1915
Apr ’24US$127.10
US$141.57
+11.4%
8.3%US$167.00US$124.00US$175.2114
Mar ’24US$132.08
US$144.64
+9.5%
10.0%US$168.00US$120.00US$171.1214
Feb ’24US$152.67
US$143.27
-6.2%
13.3%US$168.00US$114.00US$163.1415
Jan ’24US$140.89
US$126.40
-10.3%
11.7%US$157.00US$110.00US$152.4415
Dec ’23US$130.20
US$123.60
-5.1%
10.3%US$157.00US$110.00US$137.7015

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 01:09
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Universal Health Services, Inc. is covered by 40 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hua HaBaird
Adam FeinsteinBarclays
Andrew MokBarclays